Atezolizumab/durvalumab

  • PDF / 168,875 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 74 Downloads / 192 Views

DOWNLOAD

REPORT

1 S

Atezolizumab/durvalumab Atypical mycobacterial infection: 2 case reports

In a cohort, retrospective study involving data queries of the US Food and Drug Administration Adverse Events Reporting System (FAERS) pharmacovigilance monitoring database, between 1 January 2015 and 31 March 2020, two patients [ages and sexs not stated] were described, who developed atypical mycobacterial infection during treatment with atezolizumab and durvalumab respectively, [routes, dosages, indications, durations of treatments to reaction onset and outcomes not stated]. Anand K, et al. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open 5: e000866, No. 4, 18 Aug 2020. Available from: URL: http:// doi.org/10.1136/esmoopen-2020-000866

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

803503168

Reactions 26 Sep 2020 No. 1823

Data Loading...